Starpharma (ASX: SPL, OTCQX: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient.

Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Starpharma has developed a valuable technology platform known as DEP® (Dendrimer Enhanced Product), which utilises dendrimers to improve drug performance, effectiveness and safety. This innovative approach opens new possibilities for targeted and controlled drug delivery, increasing therapeutic and commercial opportunities. Additionally, the use of DEP® technology can create new intellectual property and proprietary products, extending the patent life for existing drugs.

The DEP® platform is highly versatile with broad applicability across multiple oncology approaches, including cancer drugs such as chemotherapeutics, antibody-drug conjugates (ADCs), radiotheranostics, antivirals, and other non-oncology molecules. Illustrating the value of DEP® and through its innovative approach, Starpharma has established DEP® partnerships with some of the world’s largest pharmaceutical companies and leading research institutes.

Starpharma has also developed an innovative proprietary anti-infective dendrimer called SPL7013, which has a physical mechanism of action and antiviral and antimicrobial properties. With this antimicrobial dendrimer SPL7013, Starpharma has successfully developed and launched three products in specific markets. The SPL7013 product range includes an antiviral nasal spray for cold/respiratory viruses, a topical gel for the treatment and prevention of recurrent bacterial vaginosis (BV), and an antiviral condom for sexually transmitted infections (STIs).

By leveraging its patented dendrimer technology, Starpharma strives to create innovative healthcare solutions that are commercially attractive and beneficial to patients, doctors, and healthcare providers.

Latest Reports & Presentations

Stock Listing

Starpharma is dual listed on the Australian Securities Exchange (ASX: SPL) and the OTCQX international exchange (OTCQX: SPHRY).

To view more on Starpharma from the ASX, visit www.asx.com.au/markets/company/spl

To view American Depository Receipt (ADR) prices and volumes on the OTCQX international exchange, visit www.otcmarkets.com/stock/SPHRY/overview

American Depository Receipts

ADR Radio: 1 ADR is equal to 10 Ordinary ASX shares.

Sponsored ADR: Depository Bank: BNY Mellon

Shareholder Services

The Starpharma ASX share register is maintained by Computershare Investor Services.

 Shareholders may visit the Computershare website to:

 Access the Investor Centre, which offers services including checking holdings in Starpharma and other companies, reviewing and updating personal details, etc. Log in to the Computershare Investor Centre. You will require your SRN/HIN/Holder Number and Postcode to access this site.

  • Update your communication preferences for receiving Notice of Meeting, Proxy, and Statutory Annual Reports.
  • Download forms for manually updating personal details.

Shareholder communications and meeting-related documents

Starpharma encourages all shareholders to provide an email address so we can communicate with you electronically when shareholder notices become available online for items such as meeting documents and annual reports.

Shareholders can elect to receive some or all of their communications in physical or electronic form or not to receive certain documents such as annual reports. To review your communications preferences or sign up to receive your shareholder communications via email, please update your details with our shareholder registry here.

Please note that Starpharma will only send physical meeting documents if you request a copy to be posted.

If you are a shareholder and would like a physical copy of a communication, need further information about the options available to you or have questions about your holding, please get in touch with our shareholder registry:

Computershare Investor Services Pty Limited

Postal Address: GPO Box 2975, Melbourne, Victoria 3001, Australia

Telephone (within Australia): 1300 850 505

Telephone (outside Australia): +61 (3) 9415 4000

Website: www-au.computershare.com/Investor/#Home?gcc=au

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com